References
- Papadopoulos NM, Elin RJ, Wilson DM. Incidence of gamma-globulin banding in a healthy population by high-resolution electrophoresis. Clin Chem 1982; 28(4 Pt l): 707–8
- Aguzzi F, Bergami MR, Gasparro C, et al. Occurrence of monoclonal components in general practice: clinical implications. Eur J Haematol 1992; 48(4): 192–5
- Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997; 11 (1): 71–87
- Boccadoro M, Pileri A. Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Baillieres Clin Haematol 1995; 8(4): 705–19
- Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med 1987; 82(1): 39–45
- Ligthart GJ, Radl J, Corberand JX, et al. Monoclonal gammopathies in human aging: increased occurrence with age and correlation with health status. Mech Ageing Dev 1990; 52(2–3): 235–43
- Ong F, Hermans J, Noordijk EM, et al. Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma. Ann Hematol 1995; 70(1): 19–24
- Kyle RA. “Benign” monoclonal gammopathy: after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68(1): 26–36
- Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62(8): 719–31
- Moller-Petersen J, Schmidt EB. Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy. Scand J Haematol 1986; 36(3): 295–301
- Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996; 87(3): 912–8
- Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997; 11(1): 111–31
- Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302(24): 1347–9
- Hyun BH, Kwa D, Gabaldon H, et al. Reactive plasmacytic lesions of the bone marrow. Am J Clin Pathol 1976; 65(6): 921–8
- Terpstra WE, Lokhorst HM, Blomjous F, et al. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol 1992; 82(1): 46–9
- Bartl R, Frisch B, Fateh-Moghadam A, et al. Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol 1987; 87(3): 342–55
- Solomon A. Bence Jones proteins: malignant or benign? (Editorial) N Engl J Med 1982; 306(10): 605–7
- Greipp PR. Prognosis in myeloma. Mayo Clin Proc 1994; 69(9): 895–902
- Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995; 13(1): 251–6
- Tenti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 1995; 91(3): 658–60
- Garewal H, Durie BG, Kyle RA, et al. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984; 2(1): 51–7
- Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2- microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81(12): 3382–7
- Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol 1995; 90(3): 693–6
- Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997; 11 (1): 27–42
- Frassica DA, Frassica FJ, Schray MF, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1989; 16(1): 43–8
- Holland J, Trenkner DA, Wasserman TH, et al. Plasmacytoma: treatment results and conversion to myeloma. Cancer 1992; 69(6): 1513–7